These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Polysaccharide structure dictates mechanism of adaptive immune response to glycoconjugate vaccines. Sun X, Stefanetti G, Berti F, Kasper DL. Proc Natl Acad Sci U S A; 2019 Jan 02; 116(1):193-198. PubMed ID: 30510007 [Abstract] [Full Text] [Related]
9. Moderate PEGylation of the carrier protein improves the polysaccharide-specific immunogenicity of meningococcal group A polysaccharide conjugate vaccine. Zhang T, Yu W, Wang Y, Hu T. Vaccine; 2015 Jun 22; 33(28):3208-14. PubMed ID: 25964170 [Abstract] [Full Text] [Related]
15. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers. McVernon J, Nolan T, Richmond P, Reynolds G, Nissen M, Lambert SB, Marshall H, Papa T, Rehm C. Pediatr Infect Dis J; 2012 Jan 22; 31(1):e15-23. PubMed ID: 22094636 [Abstract] [Full Text] [Related]
17. CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells. Kelly DF, Snape MD, Clutterbuck EA, Green S, Snowden C, Diggle L, Yu LM, Borkowski A, Moxon ER, Pollard AJ. Blood; 2006 Oct 15; 108(8):2642-7. PubMed ID: 16675705 [Abstract] [Full Text] [Related]